Deciphering the modes of human separase inhibition by securin and CDK1-CCNB1.

IF 2.6 Q3 ONCOLOGY

Molecular and Cellular Oncology Pub Date : 2021-09-24 eCollection Date: 2021-01-01 DOI:10.1080/23723556.2021.1975473

Pierre Raia, Jun Yu, Andreas Boland

引用次数: 1

Abstract

Accurate chromosome segregation depends on tight regulation of the protease separase, which cleaves the ring-shaped cohesin complex that entraps the two sister chromatids. We recently reported structures of human separase bound to its inhibitors securin or the cyclin-dependent kinase 1 (CDK1)-cyclin B1 (CCNB1)-cyclin-dependent kinases regulatory subunit 1 (CKS1) complex and discovered an array of molecular mechanisms that block cohesin-cleavage.

Abstract Image

查看原文本刊更多论文

解读securin和CDK1-CCNB1对人分离酶的抑制模式。

准确的染色体分离依赖于蛋白酶分离酶的严格调控，蛋白酶分离酶可以切割包围两个姐妹染色单体的环状内聚复合物。我们最近报道了人类分离酶与其抑制剂securin或细胞周期蛋白依赖性激酶1 (CDK1)-细胞周期蛋白B1 (CCNB1)-细胞周期蛋白依赖性激酶调节亚基1 (CKS1)复合物结合的结构，并发现了一系列阻断黏结蛋白切割的分子机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular and Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.